OrganoClick AB

As of June 30, 2026, OrganoClick AB carries a market capitalization of 79.52M, placing it among publicly traded companies globally. Its enterprise value stands at 162.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OrganoClick AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, OrganoClick AB has 183.22M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.52, and the price-to-book ratio stands at 7.55.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 162.23M versus a market cap of 79.52M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, OrganoClick AB maintains a current ratio of 0.42, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 517.95, indicating elevated leverage, while an interest coverage ratio of -1.25 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OrganoClick AB posted a negative return on equity (ROE) of -207.98, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.47, reflecting losses generated across the asset base. The company generates approximately 2.30M in revenue per employee across its workforce of 39.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.83 indicates how many times OrganoClick AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, OrganoClick AB recorded 70,000.00 in income tax expense. The company reported a pretax loss of -33.71M and -32.19M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, OrganoClick AB's stock has declined approximately 84.74% over the past 52 weeks. The 50-day moving average sits at 0.30, while the 200-day moving average is 0.78.

Over the twelve months ended June 30, 2026, OrganoClick AB generated 90.28M in revenue and converted that into -32.19M in net income, yielding earnings per share of -0.31. EBITDA reached -9.00M, while operating income came in at -26.44M.

As of June 30, 2026, OrganoClick AB holds 480,000.00 in cash and equivalents against 78.56M in total debt, resulting in a net debt position of 52.57M. Total book value stands at 10.53M, with working capital of -59.05M providing operational flexibility.

OrganoClick AB produced -4.15M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.92M in capital expenditures, free cash flow totaled -14.07M - equivalent to -0.13 per share.

Over the twelve months ended June 30, 2026, OrganoClick AB posted a gross margin of 15.63, reflecting its pricing power and cost economics. The operating margin of -29.29 and net profit margin of -35.66 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -30.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.20, meaning OrganoClick AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

OrganoClick AB's most recent stock split took place on August 5, 2025 with a 435:437 split ratio.

As of June 30, 2026, OrganoClick AB has an Altman Z-Score of -5.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.